TABLE I.
Agent | N | Duration | Endpoint | Outcome |
---|---|---|---|---|
Donepezil | 269 | 24 weeks | Symptoms | Negative |
Donepezil/Vitamin E | 769 | 3 years | AD | Partially positive |
Rofecoxib | 1200 | 2–3 years | AD | Negative |
Galantamine | 995 | 2 years | CDR 1 | Negative |
1062 | 2 years | CDR 1 | Negative | |
Rivastigmine | 1018 | 3–4 years | AD | Negative |
AD, Alzheimer’s disease; CDR, clinical dementia rating.